Verastem, Inc. is a biopharmaceutical company focused on developing and commercializing medicines to improve the survival and quality of life of cancer patients. The company's lead product, Copiktra (duvelisib), is a small molecule inhibitor of phosphoinositide 3-kinase (PI3K) and dual inhibitor of PI3K-delta and PI3K-gamma. Copiktra is approved by the FDA for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) after at least two prior therapies. Verastem is also developing defactinib, which is currently in Phase 1/2 clinical trials for the treatment of ovarian cancer, pancreatic cancer, and mesothelioma. The company was founded in 2010 and is headquartered in Needham, Massachusetts.